Reports Q4 revenue $397M, consensus $399.34M. “In 2023, we saw stability in our markets and resilience of our product portfolio, which demonstrates the impact of our products and technologies on restoring patients’ lives,” said Jan De Witte, president and CEO. “Despite the operational challenges last year, I am extremely proud of our colleagues around the world for remaining focused on advancing our key pillars of growth and operational excellence, and for their unwavering commitment to our customers and patients.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IART:
- Integra LifeSciences Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides 2024 Financial Guidance
- Integra LifeSciences Announces Leadership Transition Plan
- Is IART a Buy, Before Earnings?
- Integra LifeSciences to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call on February 28, 2024
- Integra LifeSciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
